Teva Pharmaceuticals Industry Ltd, an Israeli drug manufacturing company based in Tel Aviv, has announced that it has found a drug that slows down Parkinson’s disease. The drug, which is called Azilect, was run through a series of studies to determine how well it manages to combat the disease.

The study found that 1 mg tablets of the drug slow down the progression of the disease in a Phase 3 trial. According to the study, the drug seems to have no side effects and is well tolerated by the body.

This would be the first drug in the history of Parkinson’s disease that would be able to slow down its progress. And thanks to this, analysts think that Azilect will become a major success as well as a very good source of profit.

Teva Pharmaceuticals Industry’s Swedish partner Lundbeck will be the company to promote the drug on the French, British and German markets, as part of the effort to bring Azilect to the attention of European doctors.

The pharmaceuticals company also said that it plans to forward the product for extended studies to the American and European drug authorities. However, the study that the company has conducted for herself was one of the biggest concerning patients with Parkinson’s. The study, which spanned over a period of one year and a half, was carried on more that 1000 patients diagnosed with the disease.

After making its discovery public, Teva Pharmaceuticals Industry’s shares have risen 5 percent to $44.54. The trend was the same for its partner, Lundbeck.